Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass

被引:15
作者
Shirota, K [1 ]
Watanabe, T [1 ]
Takagi, Y [1 ]
Ohara, Y [1 ]
Usui, A [1 ]
Yasuura, K [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668560, Japan
关键词
blood heparin concentration; activated clotting time; heparinase ACT; cardiopulmonary bypass; coagulation and fibrinolytic systems;
D O I
10.1046/j.1525-1594.2000.06340.x
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
In cardiopulmonary bypass (CPB), despite heparin regimens in which the activated clotting time (ACT) is kept at more than 400 s, there is biochemical evidence of thrombin generation indicating activation of the coagulation system and increased fibrinolytic activity. Therefore, to reduce the coagulant activation has been one of the main issues in the improvement of CPB. The purpose of this study was to compare the heparin concentration with the ACT and to evaluate the effect of keeping higher heparin concentration on the coagulation and fibrinolytic systems during hypothermic CPB, employing moderate hypothermia (MHT) or deep hypothermic circulatory arrest (DHT). Heparin was either administered to maintain an ACT >400 s (ACT group) or to maintain a whole blood heparin concentration of 3 mg/kg (heparin group). At the lowest core temperature during CPB, the ACT and the heparinase ACT (unrelated to heparin concentration) were increased the most whereas the whole blood heparin concentration was less than half the initial concentration in both ACT groups of MHT and DHT. The thrombin-antithrombin III (TAT) content just after CPB in both MI-IT and DHT was significantly lower in the heparin group than in the ACT group. In conclusion, ACT does not reflect the whole blood heparin concentration during hypothermic CPB. Furthermore, maintenance of the higher heparin concentration during hypothermic CPB may suppress the activation of the coagulation system via thrombin inhibition. That effect was more remarkable in deep hypothermic CPB. Therefore, we believe that anticoagulation management during hypothermic CPB should be based on the maintenance of the higher blood heparin concentration.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 11 条
  • [1] ALTERATIONS OF HEMOSTASIS ASSOCIATED WITH CARDIOPULMONARY BYPASS
    BICK, RL
    SCHMALHORST, WR
    ARBEGAST, NR
    [J]. THROMBOSIS RESEARCH, 1976, 8 (03) : 285 - 302
  • [2] APROTININ THERAPY IN CARDIAC OPERATIONS - A REPORT ON USE IN 41 CARDIAC CENTERS IN THE UNITED-KINGDOM
    BIDSTRUP, BP
    HARRISON, J
    ROYSTON, D
    TAYLOR, KM
    TREASURE, T
    [J]. ANNALS OF THORACIC SURGERY, 1993, 55 (04) : 971 - 976
  • [3] BOONSTRA PW, 1994, J THORAC CARDIOV SUR, V107, P289
  • [4] DISCUSSION OF MARSHALL VM
    CONNOLLY, JE
    [J]. ANNALS OF SURGERY, 1965, 162 (03) : 373 - &
  • [5] LACK OF CORRELATION BETWEEN ACTIVATED CLOTTING TIME AND PLASMA HEPARIN DURING CARDIOPULMONARY BYPASS
    CULLIFORD, AT
    GITEL, SN
    STARR, N
    THOMAS, ST
    BAUMANN, FG
    WESSLER, S
    SPENCER, FC
    [J]. ANNALS OF SURGERY, 1981, 193 (01) : 105 - 111
  • [6] ACTIVATED COAGULATION TIME OF WHOLE BLOOD
    HATTERSLEY, PG
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1966, 196 (05) : 436 - +
  • [7] THE PLATELET-FUNCTION DEFECT OF CARDIOPULMONARY BYPASS
    KESTIN, AS
    VALERI, CR
    KHURI, SF
    LOSCALZO, J
    ELLIS, PA
    MACGREGOR, H
    BIRJINIUK, V
    OUIMET, H
    PASCHE, B
    NELSON, MJ
    BENOIT, SE
    RODINO, LJ
    BARNARD, MR
    MICHELSON, AD
    [J]. BLOOD, 1993, 82 (01) : 107 - 117
  • [8] MICHELSON AD, 1991, BLOOD S, V78, pA389
  • [9] TABUCHI N, 1993, J THORAC CARDIOV SUR, V106, P828
  • [10] HYPOTHERMIA-INDUCED REVERSIBLE PLATELET DYSFUNCTION
    VALERI, CR
    CASSIDY, G
    KHURI, S
    FEINGOLD, H
    RAGNO, G
    ALTSCHULE, MD
    [J]. ANNALS OF SURGERY, 1987, 205 (02) : 175 - 181